Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Nonviral CRISPR/Cas9 Mutagenesis for Streamlined Generation of Mouse Lung Cancer Models

ABSTRACT: Nonviral CRISPR/Cas9 Mutagenesis for Streamlined Generation of Mouse Lung Cancer Models

PROVIDER: PRJNA1048458 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27056423_1.fastq.gz	Fastqsanger.gz
	SRR27056423_2.fastq.gz	Fastqsanger.gz
	SRR27056424_1.fastq.gz	Fastqsanger.gz
	SRR27056424_2.fastq.gz	Fastqsanger.gz
	SRR27056425_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 97

Similar Datasets

Nonviral CRISPR/Cas9 Mutagenesis for Streamlined Generation of Mouse Lung Cancer Models

Project description:Functional analysis in mouse models is necessary to establish the involvement of a set of genetic variations in tumor development. Many lung cancer models have been developed using genetic techniques to create gain- or loss-of-function alleles in genes involved in tumorigenesis; however, because of their labor- and time-intensive nature, these models are not suitable for quick and flexible hypothesis testing. Here we introduce a lung mutagenesis platform that utilizes CRISPR/Cas9 RNPs delivered via cationic polymers. This approach allows for the simultaneous inactivation of multiple genes. We validate the effectiveness of this system by targeting a group of tumor suppressor genes, specifically Rb1, Rbl1, Pten, and Trp53. chosen for their potential to cause lung tumors. This polymer-based delivery platform enables the modeling of lung tumorigenesis independently of the genetic background, simplifying and expediting the process without the need for modifying the mouse germline or creating custom viral vectors.

2024-06-21 | GSE249293 | GEO

Saturating mutagenesis with assembled CRISPR-Cas9 ribonucleoprotein complexes.

Project description:The CRISPR-Cas9 system enables efficient sequence-specific mutagenesis for creating germline mutants of model organisms. Key constraints in vivo remain the expression and delivery of active Cas9-guideRNA ribonucleoprotein complexes (RNPs) with minimal toxicity, variable mutagenesis efficiencies depending on targeting sequence, and high mutation mosaicism. Here, we established in vitro-assembled, fluorescent Cas9-sgRNA RNPs in stabilizing salt solution to achieve maximal mutagenesis efficiency in zebrafish embryos. Sequence analysis of targeted loci in individual embryos reveals highly efficient bi-allelic mutagenesis that reaches saturation at several tested gene loci. Such virtually complete mutagenesis reveals preliminary loss-of-function phenotypes for candidate genes in somatic mutant embryos for subsequent generation of stable germline mutants. We further show efficient targeting of functional non-coding elements in gene-regulatory regions using saturating mutagenesis towards uncovering functional control elements in transgenic reporters and endogenous genes. Our results suggest that in vitro assembled, fluorescent Cas9-sgRNA RNPs provide a rapid reverse-genetics tool for direct and scalable loss-of-function studies beyond zebrafish applications.

2016-05-01 | E-MTAB-4143 | biostudies-arrayexpress

Nonviral CRISPR/Cas9 mutagenesis for streamlined generation of mouse lung cancer models.

Project description: Not available

| S-EPMC11252735 | biostudies-literature

Saturating mutagenesis with assembled CRISPR-Cas9 ribonucleoprotein complexes.

Project description:Saturating mutagenesis with assembled CRISPR-Cas9 ribonucleoprotein complexes.

| PRJEB12161 | ENA

Pitfalls in Single Clone CRISPR-Cas9 Mutagenesis to Fine-map Regulatory Intervals

Project description:Pitfalls in Single Clone CRISPR-Cas9 Mutagenesis to Fine-map Regulatory Intervals

| PRJNA559145 | ENA

CRISPR-Cas9 mutagenesis of U937 cells for variants resistant to Yersinia pestis intoxication

Project description:CRISPR-Cas9 mutagenesis of U937 cells for variants resistant to Yersinia pestis intoxication

| PRJNA552616 | ENA

Genetically engineered mouse models of sarcoma using CRISPR/Cas9

Project description:Generation and comparison of CRISPR/Cas9 and Cre-mediated genetically engineered mouse models of sarcoma

| PRJEB22279 | ENA

CRISPR/Cas9-targeted mutagenesis in Caenorhabditis elegans.

Project description: Not available

| S-EPMC3813849 | biostudies-literature

CRISPR/Cas9-mediated targeted mutagenesis in grape.

Project description: Not available

| S-EPMC5436839 | biostudies-literature

Genome-scale CRISPR-Cas9 knockout screens for enterovirus D68 and rhinovirus C15

Project description:H1-HeLa cells were stably transduced with lentiCas9-Blast (Addgene, Plasmid #52962) and subsequently selected using blasticidin to generate constitutively expressing Cas9 H1-HeLa cells. A single Cas9-expressing H1-HeLa clone was then transduced with lentivirus without a selection marker to stably express CDHR3 C529Y (H1-HeLa+CDHR3). A single CDHR3-expressing H1-HeLa clone was then chosen based on RT-qPCR of CHDR3 expression and RV-C15 RNA levels for mutagenesis. 300 million of the H1-HeLa cells constitutively expressing CDHR3 and Cas9 were transduced with the lentiGuide-Puro from the GeCKO v2 library at a MOI of 0.3. Cells were selected using puromycin and heterogeneous H1-HeLa knockout cell populations were subsequently pooled together. The CRISPR genetic screens were started 10 days post transduction. >1000-fold coverage of mutagenized cells (libraries A and B) was infected with either RV-C15 (MOI=1 PFU/cell) or EV-D68 Missouri (MOI=1 PFU/cell). RV-C15 infection was repeated for an additional round at 6 days post-infection. As soon as appearance of visibly viable colonies was observed, populations of virus-resistant cells were pooled and harvested. Uninfected starting populations of mutagenized cells were used as the unselected reference. Total genomic DNA from both virus-resistant and uninfected cells was respectively extracted using QIAamp DNA Mini Kit (Qiagen). The inserted guide RNA sequences were retrieved from the genomic DNA by PCR amplification. The PCR products were then purified and subjected to NextSeq platform (Illumina) next-generation sequencing.

2019-07-10 | E-MTAB-8125 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data